Sintilimab in FH-deficient Renal Cell Carcinoma

Phase 2 Unknown 37 enrolled West China Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma.

Timeline

Start: 2020-06-01
Primary completion: 2022-06-01
Completion: 2023-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous

Sintilimab in FH-deficient Renal Cell Carcinoma

Summary

Timeline

Drugs

Indications